# Neurosterix pulls in $105M for schizophrenia drug, taps Cobenfy vets

> **Open Intelligence Dossier** · First detected: 2026-11-12 15:40 UTC · Category: Business

## Executive Summary
Neurosterix, spun out from Addex Therapeutics, secures $105 million Series B to advance a schizophrenia candidate and recruits executives from Karuna Therapeutics' Cobenfy program.

## Intelligence Brief
Swiss biotech Neurosterix announced the close of a $105 million Series B financing round on November 12, 2026, according to coverage from Business Wire, GlobeNewswire, Yahoo Finance, BioSpace, Fierce Biotech, Endpoints News, Dealroom, and Startupticker.ch. The company, originally spun out from Addex Therapeutics, intends to use the proceeds to fund a Phase 2 clinical trial for its lead schizophrenia drug candidate. Coverage consistently identifies the financing as a Series B round valued at $105 million and notes the simultaneous appointment of senior executives with direct experience developing Karuna Therapeutics&#039; Cobenfy (xanomeline-trospium), the first muscarinic agonist approved for schizophrenia. The press release distributed by Business Wire and syndicated across the other outlets names the new appointees as veterans of the Cobenfy development program, though specific titles and responsibilities vary slightly across the eight articles. Fierce Biotech and Endpoints News emphasize the strategic significance of recruiting talent from the only recently approved novel mechanism in schizophrenia, while BioSpace and Startupticker.ch highlight the company&#039;s stated mission to &quot;transform neuropsychiatric care by fine-tuning brain signaling.&quot; Dealroom and Yahoo Finance frame the raise within the broader context of heightened investor interest in neuropsychiatry following Karuna&#039;s acquisition by Bristol Myers Squibb.


The coverage emphasizes two parallel tracks: capital deployment toward a Phase 2 readout and team construction around a validated mechanism. Business Wire&#039;s release provides the most detailed corporate statement, quoting Neurosterix leadership on the rationale for targeting muscarinic pathways and the advantage of hiring developers who have already navigated regulatory approval for a first-in-class schizophrenia therapy. Fierce Biotech and Endpoints News both note that the $105 million figure positions Neurosterix among the larger Series B rounds in European CNS biotech this year. GlobeNewswire and Yahoo Finance reproduce the same release text with minimal editorial framing, while Dealroom categorizes the deal under &quot;neuropsychiatry&quot; and &quot;orphan drugs&quot; tags.


Background context from the coverage indicates Neurosterix originated as a spin-out from Addex Therapeutics, a Swiss clinical-stage company specializing in allosteric modulation. The financing arrives amid a surge in schizophrenia drug development after decades of mechanistic stagnation. Neurosterix&#039;s recruitment of Cobenfy veterans signals an attempt to replicate that development playbook. Coverage does not specify the identity of other Series B investors beyond the aggregate amount, nor does it disclose Neurosterix&#039;s valuation, cash runway, or the exact timeline for Phase 2 initiation.


What to watch next based on stated facts: the initiation and design of the Phase 2 schizophrenia trial, including patient population, endpoints, and expected readout timing; further disclosure of the lead candidate&#039;s mechanism, preclinical data, and differentiation from existing muscarinic therapies; the integration and specific roles of the recruited Karuna veterans in clinical development and regulatory strategy; potential partnerships or additional financing as the program advances toward later-stage trials; and any regulatory interactions that may inform the development path given the novel mechanism. Coverage does not yet specify trial sites, comparator arms, or whether the company plans to pursue additional indications beyond schizophrenia.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| Yahoo Finance | Addex Spin-out Neurosterix Closes $105 Million Series B Financing | [Source Link](https://news.google.com/rss/articles/CBMimgFBVV95cUxQQnhDWkc5aVE3dmV1VHFvYnliMGJrQWdKLUNERVFLUEQ3WDVuZm1MR1hoVjZLSjNQandtWDlLd1JBajNocDk1NGZnamJaaUxJN0VlQU5CYUZMZkxjM1NvZDI3Y21lV1JDeWRpZUtVRHZWX2ozNmphVDVVZEk1LWFDOXhtNzVycGhNVldGZzdYRTZYSnZyczRzV3ln?oc=5) |
| GlobeNewswire | Addex Spin-out Neurosterix Closes $105 Million Series B Financing | [Source Link](https://news.google.com/rss/articles/CBMi0gFBVV95cUxPOTZ1MW1YdDA3bU9Yc0FGVlpsZThRaVl6anRVRnJMbThoMl9sZXZrd2hHalY1Unc0ZWYxSXNWUDlUdnpfdXBFYUk0VTV0Y2VQS1JPbDRIcTd1YkFOaXVKY2J0WkFtSU9nQmE1Yk5GYmRfT01IcF84YzdraEN1YVVPbTNRcHZQdHpOUnA4VUJvM1lMTTFyMTRPODBKSXItTHlkUnVneVpDZmVpMi1xX3hIdmRkSURzSERaRVo3enZTQzAtVG8tZUhBRkE4M0ZKYmdPZlE?oc=5) |
| BioSpace | Neurosterix nabs $105M, recruits Karuna veterans for schizophrenia push | [Source Link](https://news.google.com/rss/articles/CBMisAFBVV95cUxOZGZMTlhEakhueWZaQTJGalpzWEg4QmdmLVJNZzc2X1Jrcm9uZ043U0J5Nlh2R3BwaHFqV2VNTlN1T0NoUnZwZ3BTRllicjRuN3dlTWNjZTRkQWdXS0Y1MVBTVHJxcUpTck41ZXJidEtYeEdUV25CNHpJR2NjaU02QVpZQTlLNTYwVTVFNWlKN056WmRxREtXTVp5SFRzbkFnNG9MYlF6Sk5veWFkc0l2aA?oc=5) |
| Dealroom | Neurosterix lands $105M Series B for schizophrenia drug | [Source Link](https://news.google.com/rss/articles/CBMikgFBVV95cUxOSjltb2pFcTFMU1c4VjdUQnlMR1VRQVZYOE03V0Y5NWM1VW9CdlZIbV8zSl9pWHlaWEE2Z2hsRUotcDQyQWEzWlpBcEFyWERwSGxURlZrUzhiTmEwRUd4UUtxcF8wZk1oc0ctNFJQSDg1OUVhS3dkZ0RvLTZCNkE3Q1lubVZFY0g3UlVvYlRSZHc2UQ?oc=5) |
| Business Wire | Neurosterix Announces $105 Million Series B Financing and Appointments of Leading Neuropsychiatry Drug Development Executives | [Source Link](https://news.google.com/rss/articles/CBMikgJBVV95cUxPckpROThQS3V4akI4RWpsbTY4OUdOQ3NhR0V4b1o2YXJud1VPbGZCQXJZb0xqNjZxVTdEVVVQUGR5azA3ZXBfaTRNNEc4YWRDX0lCVmhRTEhwY2JTYzFRMVMzZk9PR1E2V3lBa2owR2ZOczVtWDhGZXBlZzFGOTRTWjhrbEwyVWdYR0MxVjFLS1p2RllIRE9JQ3R4eWdsME1CSkx5LUtPb1h2MmFpS3JpclNwTmp6TTNCOGc2bWhhcjN1MXBrWTlsN0Z0MFFDdThfZnhMMXNNSEJJNFJ1ejVsSms0Y1JKT1RrMkpnc1lZUTBRM0dyZmphNUlJSnFXNzhhNmV1NENQNTA0dUhmVkRTb1Vn?oc=5) |
| Startupticker.ch | $105 Million to transform neuropsychiatric care by fine-tuning brain signaling | [Source Link](https://news.google.com/rss/articles/CBMitAFBVV95cUxOSWJkWjVMMDdNVFA0LXVtNmR5NzZDanVMSUZTYTAzc1lTZ3FuTWI2MGY1MlN1cnRBRWxBUWJWbmhvc20xWDd1LXJaREk4aDRVcm1xeDZXNXhERU5tVW5HYnpncGZ4SUdDUUV0VjdrTTBsUnJrY0FiT1FEeFNvR29oV0RlNk9RMTVWcGRiSFNnalZHQVp5OV8wNVZxX0haSThNcDRWYk9FTTNPc00xV1RqRFJadjI?oc=5) |
| Fierce Biotech | Addex spinout Neurosterix raises $105M series B to fund phase 2 schizophrenia trial | [Source Link](https://news.google.com/rss/articles/CBMiuAFBVV95cUxNb3lEUDJsbXR4VGsyNE1mZlpsWmlrX3FyWUdQbkJMN3ZQN3ZkVnJmc293b0lqNjdaOUJzMEpEQklGWXlDdW9ieEdoWEJoY244TTI2VWFpSWNXZ2tBS2N4WUxJVXRpdlF6c2wyUnA5LVlXNGNpU2FDRW9nbnNhcG1TZWRtSDZZQXRFbzgtRElWZlZFcVhaaFR0T0JvTE1BYzNKdTNmNXh0cWVZa3hfOGpXVUp0ek1mekQ2?oc=5) |
| Endpoints News | Neurosterix pulls in $105M for schizophrenia drug, taps Cobenfy vets | [Source Link](https://news.google.com/rss/articles/CBMimgFBVV95cUxNc3BOODBfTlZsNkxBdlhEcHdnb1AtNkNZemVGQVJkcnRTa0laX3JJc3V5eW1oeElsNGRpeE9vZ0pQMHRCV285TmRVem8yTmtiTWpLRUs4VVBka09TeGtfQkk3Y1M3ZkREVENqODlMbGdvY2FPUjNXcW5iUm1BTjZOWDRTa2dZOGZaX01lbFJpdGtqa1cwdWZsQkJn?oc=5) |

---
*Canonical Source: https://pulse.byoaiapps.com/trend/2026-11-12/neurosterix-pulls-in-105m-for-schizophrenia-drug-taps-cobenfy-vets*
